Cabergoline

Evidence Level: L5 Predicted Indications: 4

Table of Contents

  1. Cabergoline
    1. Pharmacist Assessment Report
    2. Cabergoline: Dopamine D2 receptor agonist → progeria-short stature-pigmented nevi syndrome
    3. One-Sentence Summary
    4. Quick Overview
    5. Why is This Prediction Reasonable?
    6. Clinical Trial Evidence
    7. Literature Evidence
    8. India Market Information
    9. Safety Considerations
    10. Conclusion and Next Steps
    11. Disclaimer

Pharmacist Assessment Report

Cabergoline: Dopamine D2 receptor agonist → progeria-short stature-pigmented nevi syndrome

One-Sentence Summary

Cabergoline is a dopamine D2 receptor agonist that is already marketed in India as oral tablets. The TxGNN model predicts it may be effective for progeria-short stature-pigmented nevi syndrome. However, no clinical trials and no publications support this prediction, so it rests on the model score alone.

Quick Overview

Item Content
Original Indication Not recorded in the local data
Predicted New Indication progeria-short stature-pigmented nevi syndrome
TxGNN Prediction Score 0.9906
Evidence Level L5
India Market Status Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products at least 20
Recommended Decision Hold

Why is This Prediction Reasonable?

Cabergoline acts by stimulating dopamine D2 receptors. The data compiled for this report contain no further detail on its mechanism of action.

No plausible mechanistic link between D2 receptor agonism and this syndrome can be established from the available data. The only support is the model’s prediction score of 0.9906. This score is a model ranking and should not be read as a probability of clinical benefit.

The prediction is therefore a hypothesis only. It would need independent biological support before any clinical interpretation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Cabergoline is marketed in India. Valid licences exist for single-ingredient oral tablets, supplied in strips of 2 or 4 tablets by multiple manufacturers. The licence records may be partial. The local records carry no approved-indication text for these products.

Safety Considerations

  • Drug Interactions: The interaction screening completed and returned 60 interacting drugs. The main ones are:
    • Major: lorcaserin and clarithromycin.
    • Moderate: metoclopramide.

For other safety information, please refer to the package insert.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has no supporting clinical trials or publications and no identifiable mechanistic link. The only support is the model score, so the evidence level is L5.

To proceed, the following is needed:

  • A biological rationale connecting D2 receptor signalling to the pathology of this syndrome.
  • Preclinical or case-level evidence of cabergoline activity in this condition.
  • Detailed mechanism of action data and package-insert safety information (warnings and contraindications).
  • A safety review of long-term cabergoline use in this population, given the interaction signals above.

    Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.